Mrs Jagdeep Singh

Mrs Jagdeep Singh relocated to Guildford in July 2020 and was appointed as a Consultant Oncoplastic Breast Surgeon at Surrey and Sussex Healthcare NHS Trust in August 2020.

Training and Appointment

Mrs Singh completed her pre-clinical training at Somerville College, University of Oxford and was awarded a BA (Hons) in Physiological Sciences in 2002.

She went on to complete her clinical training at University College London and qualified (MBBS) in 2005, then finished her Higher Surgical Training in the West Midlands, where she focussed on specialist breast training at the major university teaching hospitals including University Hospitals Birmingham NHS Foundation Trust.

Mrs Singh worked as a Consultant Oncoplastic Breast Surgeon at the Queen Elizabeth Hospital, part of University Hospitals Birmingham NHS Foundation Trust, between June 2018 and July 2020. She was the Breast Angiosarcoma Lead for the West Midlands and established the regional Electrochemotherapy service at the Queen Elizabeth Hospital for breast cancer patients with skin metastases.

She was awarded the Silver Medal in the European Board of Surgery Examinations in Breast Surgery in 2018. 

Research and publications

In 2012 Mrs Singh was awarded a Medical Doctorate (MD) from the University of Manchester for her research into breast cancer stem cell regulation.

She received a Royal College of Surgeons Surgical Research Fellowship (2010) and the Royal College of Surgeons Stefan Galeski Travelling Fellowship (2011).

Her research led to several high impact factor publications and international presentations, and she was presented with the Allen Edwards Research Prize at the British Association of Surgical Oncology (BASO) Scientific Conference in 2011.

She was selected to join the National Cancer Research Institute Breast Clinical Studies Group through the Trainee Scheme in 2016 and has continued to engage in clinical research. Mrs Singh was the Chief Investigator of the National Mastectomy Decisions Audit (MasDA), a multicentre prospective observational study which evaluated recommendations for mastectomy by UK multidisciplinary teams.

She is a steering group member of the Neoadjuvant Systemic Treatment (NeST) study and the Breast Angiosarcoma Surveillance Study (BRASS). Her research has led to many publications.

• Assesses, counsels and manages patients with a family history of breast cancer and those undergoing breast screening
• Assessing, investigating and managing patients with benign and malignant breast conditions.

Breast cancer operations

• Therapeutic mammoplasty (cancer surgery combined with re-shaping of the breast to give optimal cosmesis)
• Mastectomy (simple, skin-sparing, skin-reducing, nipple-sparing, risk-reducing)
• Wide local excision (lumpectomy)
• Sentinel lymph node biopsy
• Immediate implant-based breast reconstruction and immediate-delayed breast reconstruction utilising expanders and nipple reconstruction
• Axillary node clearance.

Benign breast operations

• Symmetrising mammoplasty
• Mastopexy (breast uplift)
• Removal of implant, capsulectomy
• Lipomodelling (fat transfer)
• Excision of benign breast lesions
• Diagnostic excisions
• Scar revision surgery and diagnostic biopsy of axillary lymph nodes
• Duct surgery.

• Royal College of Surgeons of England
• Association of Breast Surgeons
• Women in Surgery.